Research progress of breast cancer with low HER2 expression / 国际肿瘤学杂志
Journal of International Oncology
; (12): 513-516, 2022.
Article
in Chinese
| WPRIM (Western Pacific)
| ID: wpr-954313
Responsible library:
WPRO
ABSTRACT
Breast cancer with low expression of human epidermal growth factor receptor 2 (HER2) has unique biological behaviors. Compared with HER2-zero breast cancer, there are significant differences in molecular subtype and gene expression between the two categories of breast cancer. Novel antibody-drug conjugates represented by T-DXd provide a new treatment option for patients with HER2-low breast cancer, and relevant clinical trials are continuing. At present, the relationship between HER2-low status and prognosis of breast cancer patients remains controversial. In-depth research into HER2-low breast cancer will help further improve clinical outcomes for this population.
Full text:
Available
Database:
WPRIM (Western Pacific)
Language:
Chinese
Journal:
Journal of International Oncology
Year:
2022
Document type:
Article